Research Information Only — Content is for educational purposes only and does not constitute medical advice. No compound in this hub is FDA-approved for longevity indications discussed. Consult a qualified physician before use.
Biological aging is not a single process. Peptide-based longevity research targets four distinct molecular axes: telomere/epigenetic (Epithalon's telomerase activation; GHK-Cu's Yamanaka factor reversal), hormonal decline (Sermorelin's GHRH agonism; Ipamorelin's pulsatile GH restoration), cellular protection (BPC-157's cytoprotective signaling), and immune aging / thymic involution (Thymosin α1's thymic function restoration). Rational longevity peptide use requires understanding which axis a given patient's aging phenotype is driven by — not a one-compound-fits-all approach.
Molecular Axes of Aging
Where Longevity Peptides Act
Telomere / Epigenetic
Epithalon · GHK-Cu
Telomerase induction via TERT upregulation; epigenetic age reversal via Oct4/Sox2/Klf4 activation (Yamanaka factors)
GH Axis / Hormonal
Sermorelin · Ipamorelin
GHRH agonism and selective GH secretagogue activity; restoration of pulsatile GH release reduced in somatopause
Thymic involution reversal; CD4+ T-cell restoration; cancer immunosurveillance maintenance in aging immune system
Research Profiles
Longevity Hub Compounds
Seven compounds organized by their primary longevity axis. Active profiles are available now; cross-listed compounds are profiled in their primary hub but included here for their longevity-relevant mechanisms.
N-terminal fragment of endogenous Growth Hormone-Releasing Hormone (GHRH). FDA-approved as Geref for pediatric GH deficiency diagnosis (now discontinued; compounding available). Stimulates pulsatile GH release from pituitary somatotrophs via GHRHR. Used in somatopause for restoration of physiological GH pulses — the age-associated decline in pulsatile GH release that accompanies IGF-1 reduction. Distinguished from direct GH injection by preserving the pituitary's natural pulsatile secretion pattern.
GHRH AgonistGH Pulse RestorationFormer FDA Approval
Profile Coming Soon
Longevity Hub · GH Secretagogue · Coming Soon
Ipamorelin
GH Secretagogue · 5 aa · ~711 Da
Selective pentapeptide GH secretagogue with high selectivity for the GHSR-1a receptor. Stimulates GH pulse without significant co-stimulation of cortisol, prolactin, or ACTH — distinguishing it from earlier GH secretagogues. Most commonly combined with Sermorelin or CJC-1295 for synergistic pituitary stimulation. Phase I clinical safety data published; no FDA approval; frequently compounded. Profile in development.
Mitochondrial ORF of 12S rRNA Type-c · 16 aa · ~2,174 Da
Mitochondrially-encoded peptide from the 12S rRNA small subunit ORF. Regulates nuclear gene expression via AMPK activation; improves insulin sensitivity; anti-obesity and metabolic regulation effects in animal models. Circulating MOTS-c declines with age and increases with exercise. Crosses the blood-brain barrier. Phase I data emerging. The intersection of longevity, metabolic, and exercise physiology in a single peptide.
Biological aging is a multi-dimensional process. Effective longevity peptide application requires identifying which aging axis or axes are clinically predominant in a given patient — not applying a single compound to "aging" as a monolithic target. These four axes are supported by the most robust evidence base within the peptide research literature.
Telomere & Epigenetic
Cellular Age Reversal
Telomere shortening with each cell division is the clock of cellular aging — when telomeres reach critical length, cells enter senescence or apoptosis. TERT (telomerase reverse transcriptase) can rebuild telomere length but is suppressed in most somatic cells. Epigenetic aging (the Horvath Clock, measuring DNA methylation drift) is a parallel and correlated measure of cellular age that is partially reversible. Epithalon induces TERT expression; GHK-Cu activates Yamanaka factors (Oct4, Sox2, Klf4) — partial epigenetic reprogramming markers that reset methylation age in cell culture models.
Primary compounds: Epithalon, GHK-Cu
GH Axis & Somatopause
Hormonal Aging
Growth hormone secretion from the pituitary declines with age — a process called somatopause, analogous to menopause for the GH axis. GH pulses that are robust in youth become attenuated in frequency and amplitude after age 30, with corresponding declines in IGF-1. The downstream consequences include increased visceral adiposity, decreased lean muscle mass, reduced bone density, impaired recovery, and reduced exercise capacity. GHRH analogues (Sermorelin) and GH secretagogues (Ipamorelin) restore pituitary GH secretion through the body's natural regulatory mechanisms — fundamentally different from exogenous GH injection.
Inflammaging — the chronic, low-grade, sterile inflammatory state that accompanies aging — is now recognized as a central driver of age-associated pathology: cardiovascular disease, neurodegeneration, sarcopenia, and metabolic dysfunction all have inflammaging as a contributing mechanism. The gut microbiome's age-associated dysbiosis is a major inflammaging amplifier, with barrier disruption releasing endotoxin (LPS) systemically. BPC-157's cytoprotective effects on intestinal epithelium, its VEGFR2/NO signaling, and its neuroendocrine protection converge on this axis.
The thymus — where T-lymphocyte education occurs — begins involuting (shrinking, replaced by fat) in adolescence, accelerating after age 40. Thymic involution depletes the naïve T-cell repertoire, reducing the immune system's ability to recognize novel pathogens and aberrant (pre-cancerous) cells. This is a primary driver of cancer susceptibility, vaccine unresponsiveness, and increased viral severity in elderly populations. Thymosin α1 activates dendritic cells and restores T-cell maturation — the most clinically established approach to targeting this axis.
Primary compounds: Thymosin α1 (cross from Immune Hub)
Clinical Guidance
Indication-to-Compound Matrix
Matching the patient's dominant aging phenotype to the most relevant compound axis. This matrix represents evidence-informed clinical reasoning, not FDA-approved indications. Physician evaluation of individual patient history, labs, and contraindications is required before any consideration of these investigational compounds.
Clinical Scenario / Phenotype
Primary Axis
Epithalon
GHK-Cu
Sermorelin
BPC-157
Thymosin α1
Accelerated cellular aging Shortened telomeres on direct testing; high Horvath clock age gap
Post-chemotherapy immune recovery Lymphopenia, low CD4:CD8, NK depletion after cancer treatment
Immune Aging
Adjunct
Tissue repair
Adjunct GH
Adjunct
Primary
Chronic gut inflammation / dysbiosis Elevated zonulin, gut permeability markers, chronic LPS elevation
Inflammaging
Adjunct
Adjunct
Not indicated
Primary
Adjunct
Skin aging — photodamage, collagen loss Visible aging signs amenable to topical and systemic repair
Epigenetic + Structural
Systemic adjunct
Primary
Adjunct
Adjunct
Not indicated
Longevity stack — healthy aging optimization No specific pathology; laboratory-guided preventive longevity strategy
Multi-axis
Consider
Consider
If GH low
Adjunct
If CD4 low
Active autoimmune disease SLE, RA, MS, IBD, psoriasis with active immunopathology
Contraindication check
Caution (TLR9)
Topical safer
Possible
Mucosal data
Avoid (immune activation)
Note on the longevity stack scenario: "Healthy aging optimization" is the most common patient presentation in longevity medicine, and also the one with the least direct evidence from compound-specific trials. Evidence for these compounds derives largely from disease states (HBV, cancer, wound healing) and is extrapolated to optimization contexts. The precision of laboratory-guided selection (telomere testing, IGF-1, GH stimulation test, T-cell subset analysis) substantially improves rational compound selection over protocol-based approaches.
Primary Literature
Key Published Studies
Epithalon and GHK-Cu have the deepest research records in the longevity peptide literature, with Khavinson et al.'s decades of pineal peptide research and Pickart's pioneering GHK-Cu work. Sermorelin has established FDA-approval history for pediatric GH deficiency diagnosis. The following studies are foundational for physician evaluation.
Epithalon
Peptide Epitalon Activates Chromatin at the Promoter Region of Human Telomerase Reverse Transcriptase Gene in Human Embryonic Fibroblasts
Khavinson V, et al. Neuroendocrinology Letters. 2003; 24(6): 394–398.
Direct mechanistic demonstration of Epithalon's TERT gene activation: Epithalon (Ala-Glu-Asp-Gly) induced chromatin decondensation at the TERT promoter in human embryonic fibroblasts, correlating with increased telomerase activity measured by TRAP assay. Telomere length extension confirmed in treated vs. control cells. Foundational paper establishing the TERT mechanism underlying Epithalon's telomere effects.
Epithalon
Epithalamin and Epitalon Inhibit Mammary Carcinogenesis in Mice: Effect on Mutagenesis and DNA Damage
Anisimov VN, Khavinson V, et al. Carcinogenesis. 2002; 23(8): 1293–1297.
Carcinogenesis suppression study in MMTV transgenic mice: Epithalon administration significantly reduced mammary tumor incidence and multiplicity vs. control (p<0.01). Proposed mechanism: telomerase-mediated stabilization of genomic integrity in pre-neoplastic cells, combined with oxidative DNA damage reduction. Part of the series of Khavinson oncology papers supporting Epithalon's anti-cancer longevity mechanism.
Epithalon
Clinical and Immunological Effects of Epithalamin (Pineal Peptide Preparation) in Elderly Subjects
Clinical study in elderly subjects (n=79, mean age 71): pineal peptide preparation (containing Epithalon analogues) significantly improved NK cell cytotoxicity, CD4:CD8 T-cell ratio, melatonin secretion, and reduced multiple cancer risk markers over 12 months. Primary human clinical evidence for Epithalon's immune-aging and NK cell restoration effects — the most comprehensive published human data from the Khavinson group.
GHK-Cu
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed Research International. 2015; Article 648108.
Systematic gene expression analysis using published microarray datasets: GHK modulated 31.2% of genes identified as key to aging in a meta-analysis — counteracting the aging gene expression signature. Upregulates 16 of the top 50 genes downregulated in aging tissue; downregulates 28 genes elevated in aging and cancer. Documents GHK-Cu's Yamanaka factor (Oct4, Sox2, Klf4) activation — the partial epigenetic reprogramming mechanism central to its age-reversal hypothesis.
GHK-Cu
The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging
Pickart L, Margolina A. Oxidative Medicine and Cellular Longevity. 2018; Article 1279450.
Comprehensive review synthesizing GHK-Cu's multi-axis aging biology: oxidative stress modulation via Nrf2/antioxidant gene induction; neurotrophin upregulation (BDNF, NGF); anti-inflammatory cytokine modulation; telomerase activator role synergistic with Epithalon in dual-compound protocols. Documents the physiological decline of plasma GHK-Cu from ~200 ng/mL (age 20–25) to ~80 ng/mL (age 60+). Primary review reference for GHK-Cu's longevity mechanisms.
Sermorelin
Sermorelin Acetate for the Treatment of Adult Growth Hormone Deficiency: A Randomized, Placebo-Controlled Trial
Walker RF. Clinical Interventions in Aging. 2006; 1(4): 307–308.
Adult-indication Sermorelin data: nightly SC Sermorelin in GH-deficient adults improved body composition parameters (lean mass increase, visceral fat reduction) with a side-effect profile substantially superior to direct GH injection — particularly in terms of insulin resistance induction, which is significantly less with GHRH agonism than with exogenous GH. Supports the preference for Sermorelin over GH injection in age-associated somatopause contexts.
Administration Reference
Routes & Administration Considerations
General administration routes, cycling concepts, and pharmacological considerations relevant to physician evaluation of these compounds. This is not prescribing guidance and does not specify amounts or schedules — any decision to use these compounds, and at what dose, is an individualized physician determination based on patient history, labs, and current sourcing/quality standards. Compounds without active profiles (Sermorelin, Ipamorelin) are summarized here for completeness.
Epithalon
Pineal Tetrapeptide · Telomerase Activator
Route
Studied via both IV administration (Khavinson's original clinical research) and SC administration (modern compounding practice). As a short tetrapeptide, oral bioavailability is precluded by first-pass proteolytic degradation; intranasal delivery is not established for this compound.
Cycling Concept
Published Khavinson protocols use short cyclical courses rather than continuous administration, repeated at intervals across the year. No standardized Western cycle frequency has been established outside the original Russian clinical research, and long-term continuous administration has not been studied.
Most published Epithalon human data uses Epithalamin (the natural pineal extract blend) rather than pure synthetic Epithalon — extrapolating anything from extract-based research to pure synthetic use requires physician judgment and caution.
GHK-Cu
Copper Tripeptide · Epigenetic + Structural
Topical
Well-established cosmeceutical concentration range with documented dermal penetration. Multiple commercial preparations available. Anti-aging and wound healing are the primary indications for this route.
SC Systemic
No randomized systemic trial has established a dosing standard for this route — systemic use is derived from safety-focused dose-escalation studies and clinical practice reports rather than efficacy-driven RCTs. Any systemic use is an individualized physician decision paired with copper monitoring.
Duration
Systemic use in practice reports tends to be time-limited rather than indefinite; topical use is supported for ongoing use in the cosmetic literature. Cycling vs. continuous systemic administration remains unstudied.
Copper Load
Systemic copper loading is the central safety concern with SC/IV use, because the Cu²⁺ in GHK-Cu dissociates in vivo. Serum copper and ceruloplasmin monitoring is advisable for any systemic use, with the physician keeping cumulative copper exposure within normal physiological handling capacity.
Topical GHK-Cu safety is extensively documented; systemic safety data is derived from extrapolation and limited practice reports. Copper monitoring is the principal systemic safety concern.
Sermorelin
GHRH(1-29) · GH Axis Restoration
Administration Pattern
Nocturnal SC administration is used in published protocols to coincide with the physiological GH pulse, since GH is primarily secreted during slow-wave sleep stages. Any specific amount and schedule is an individualized physician determination guided by baseline and follow-up IGF-1.
Diagnostic Use
The former FDA-approved Geref label specified a weight-based IV dose for clinician-administered GH stimulation testing — a diagnostic procedure distinct from, and not a basis for, ongoing SC somatopause use.
Monitoring
IGF-1 at 4–6 weeks (primary efficacy marker); fasting glucose and HbA1c (GH increases insulin resistance); follow IGF-1 to low-normal range — avoid supraphysiologic IGF-1 elevation.
Duration
Multi-month minimum for a meaningful IGF-1 effect to become assessable; pituitary tachyphylaxis (desensitization) is theoretically possible with continuous GHRH-R stimulation, which is why cycling approaches are discussed in practice.
Sermorelin's former FDA approval (Geref, withdrawn for commercial reasons not safety concerns) provides a more robust regulatory history than most longevity peptides. The compounded preparation is the only current US access point.
Ipamorelin
GH Secretagogue · GHSR-1a Selective
Administration Pattern
SC administration is typically timed to a fasted state, since GH release is blunted by elevated insulin, with bedtime dosing preferred to align with the primary physiological GH pulse. Any specific amount and schedule is an individualized physician determination guided by IGF-1 response.
Combination Use
Concurrent SC administration with Sermorelin (or CJC-1295) is discussed in published combination approaches; dual GHSR-1a plus GHRHR activation is reported to produce a larger GH pulse amplitude than either compound alone, which may allow lower individualized amounts of each versus monotherapy.
Selectivity
Superior cortisol and prolactin selectivity profile vs. older GHS peptides (GHRP-2, GHRP-6). Published Phase I data shows <10% elevation in cortisol or prolactin at therapeutic exposure — primary advantage over predecessor secretagogues.
Monitoring
Same IGF-1-centered monitoring as Sermorelin; glucose and insulin resistance surveillance. Water retention from GH effect is the most common patient-reported side effect.
No FDA approval or IND for any indication. Entirely compounded market in the US. Evidence base substantially thinner than Sermorelin — rely on published Phase I data and mechanism pharmacology.
Laboratory Guidance
Lab Monitoring Protocols
Longevity peptide protocols require laboratory oversight for two reasons unique to this category: the theoretical malignancy concern with TERT-activating compounds (Epithalon), and the IGF-1 cancer risk ceiling with GH-axis secretagogues (Sermorelin, Ipamorelin). The monitoring framework below is derived from clinical trial procedures and pharmacological reasoning — no longevity peptide has an FDA-approved monitoring protocol. All parameters require physician interpretation in the context of the individual patient.
Epithalon
TERT Activator · Telomere Longevity Axis
Baseline (before first cycle)
CBC with differential (NK cell baseline; Khavinson data shows NK restoration)
ANA with reflex titer (immune activation baseline; exclude active autoimmune disease)
Comprehensive metabolic panel (LFTs, BUN/Cr; renal and hepatic clearance baseline)
TSH (thyroid status; Epithalon has pineal/endocrine pleiotropic effects)
PSA (men ≥ 40); CA-125 (women with ovarian cancer risk factors) — TERT concern in active malignancy
New malignancy diagnosis (absolute contraindication — TERT activation in active cancer) · ANA > 1:320 with new symptoms · Unexplained CBC changes with lymphocyte expansion
Annual cycle protocol — reassess baseline labs before each new cycle. Biological age testing (epigenetic clock, telomere length) is recommended at baseline for outcome tracking.
GHK-Cu
Copper Tripeptide · Epigenetic + ECM Axis
Baseline (SC/IV dosing only — topical requires no monitoring)
Topical GHK-Cu (0.1–2% cosmeceutical formulations): no systemic absorption concern; no laboratory monitoring required. Monitoring applies exclusively to SC or IV research use.
Sermorelin
GHRH(1–29) Analogue · GH Axis Restoration
Baseline
IGF-1 with age-specific reference (critical: use age-decade-specific ranges; low-normal target — NOT upper quartile)
IGF-1 > 300 ng/mL or above age-adjusted upper limit · Fasting glucose > 126 mg/dL (new diabetes) · Signs of acromegaly: jaw growth, enlarged hands/feet, joint pain, coarse facial features · New pituitary mass on imaging
Standard US compounded supply uses Sermorelin acetate. Geref (Sereno) was FDA-approved 1997–2008; discontinuation was commercial, not safety-driven. Off-label compounded use is not FDA-monitored.
IGF-1 (same age-specific target range as Sermorelin; low-normal for age)
Fasting glucose + HbA1c (GH-effect insulin resistance monitoring, same as Sermorelin)
AM cortisol (Ipamorelin's selectivity advantage over GHRP-2/GHRP-6 is minimal cortisol stimulation — verify baseline)
Prolactin (GH secretagogues can elevate prolactin; establish baseline before therapy)
On-therapy (6 weeks, then quarterly)
IGF-1 (target same as Sermorelin; combination use lowers dose needed for equivalent IGF-1 elevation)
Prolactin at 6 weeks (target: < 20 ng/mL men / < 25 ng/mL pre-menopausal women)
AM cortisol (confirm cortisol-sparing advantage is maintained — should be stable from baseline)
Fasting glucose at 3 months; HbA1c at 6 months
Discontinuation Triggers
IGF-1 > 300 ng/mL or above age-adjusted upper limit · Prolactin > 25 ng/mL men / > 30 ng/mL women · Glucose intolerance (fasting glucose > 126 mg/dL) · Disproportionate water retention or joint complaints at dose
Ipamorelin is the preferred GHSR-1a agonist over GHRP-2 and GHRP-6 precisely for its cortisol and prolactin selectivity. If AM cortisol is rising significantly on therapy, consider compound authenticity or substitution.
Combination Protocols
Multi-Axis Longevity Protocols
The four aging axes are complementary — combination protocols targeting more than one axis simultaneously are rational when a patient presents with multiple aging phenotypes confirmed by laboratory evaluation. The protocols below have pharmacological rationale but limited direct clinical combination data. No published RCTs have evaluated any of these specific combinations.
Epithalon induces TERT (telomerase reverse transcriptase), rebuilding telomere length in somatic cells. GHK-Cu activates Yamanaka factors (Oct4, Sox2, Klf4) and modulates the aging gene expression signature. These two compounds target different but complementary aspects of cellular aging — Epithalon at the chromosome level (telomere) and GHK-Cu at the epigenetic/transcriptional level. Proposed sequencing: concurrent SC Epithalon cycles + daily topical and/or SC GHK-Cu.
Monitoring
Telomere length testing (SpectraCell, Life Length) at baseline and post-cycle; epigenetic age testing (Horvath Clock methylation assay) if available; CBC to assess NK restoration (Epithalon) and WBC differential.
No pharmacokinetic interaction data; combination is additive by mechanism, not synergistic in proven studies. Copper monitoring warranted if SC GHK-Cu is used at higher doses concurrently.
Sermorelin (GHRH analogue) binds the pituitary GHRHR receptor, priming somatotroph cells for GH secretion. Ipamorelin (GHSR-1a agonist) simultaneously stimulates a separate receptor pathway, amplifying the GH pulse. Dual-receptor stimulation produces larger GH pulses than either compound alone — a well-characterized pharmacological synergy. Combined bedtime SC injection; lower doses of each required vs. monotherapy for equivalent IGF-1 response.
Monitoring
IGF-1 at 6 weeks and 3 months (target: low-normal range for age); fasting glucose and HbA1c at 3 months (GH-mediated insulin resistance); AM cortisol (Ipamorelin selectivity advantage — should remain stable).
Both compounds act on GH axis — risk of supraphysiologic IGF-1 elevation if dose is not monitored. IGF-1 above the physiological range is a cancer risk concern. Cycle (3 months on, 1 month off) is standard practice to preserve pituitary sensitivity.
Epithalon restores NK cell cytotoxicity in aging subjects (Khavinson human data). Thymosin α1 restores CD4+ T-cell numbers and CD4:CD8 ratio via thymic DC and T-cell activation. Together, these two compounds target both NK cell (innate immune surveillance) and adaptive T-cell (antigen-specific immune memory) arms of immune aging — complementary coverage across the immune aging spectrum. Relevant for cancer immunosurveillance optimization in the post-40 aging patient.
Monitoring
CBC/differential; CD4+ T-cell count and CD4:CD8 ratio; NK cell count (CD56+/CD16+); ANA screen at baseline before initiating Tα1 component (immune activation contraindication screen).
Both compounds activate immune function — combination is not appropriate in autoimmune conditions, organ transplant patients on immunosuppression, or patients with known elevated inflammatory markers without specialist evaluation. The immune activation is additive by mechanism.
Physician Reference
Biological Age Testing Framework
Longevity peptide selection and monitoring cannot be rationalized without a baseline biological age assessment. Chronological age is a poor proxy for the aging phenotype driving the patient's presentation. Three categories of testing currently offer clinically actionable data — each measures a different aspect of biological aging and informs different compound priorities.
Epigenetic · DNAm Clock
DNA Methylation Biological Age
What It Measures
Methylation patterns across the genome predict biological age. Different algorithms measure different constructs: static age (Horvath Clock — validated in 50+ tissues), mortality pressure (GrimAge — strongest predictor of lifespan), and pace of aging (DunedinPACE — sensitive to intervention over 12 months).
Clinical Algorithms
Horvath Clock (2013) — 353 CpG sites, tissue-universal, extensively replicated · GrimAge (2019) — plasma protein + methylation composite; predicts time-to-death independent of chronological age · DunedinPACE (2022) — real-time pace-of-aging; recommended for intervention monitoring
Commercial Labs
TruDiagnostic (TruAge COMPLETE — includes all three algorithms) · Elysium Health (Elysium Index) · Foxo Health
Limitation
Not yet reimbursed; research-grade clinical utility. DunedinPACE requires serial testing — a single value is less informative than trajectory.
Compound Signal
Horvath age > chronological by ≥ 3 years → GHK-Cu priority (Yamanaka factor epigenetic reversal) · Elevated DunedinPACE → multi-axis intervention including GH axis (Sermorelin/Ipamorelin)
Telomere · Chromosome Length
Telomere Length Assessment
What It Measures
Length of the protective telomere caps on chromosome ends (TTAGGG repeats). Telomere shortening with cell division is one of the hallmarks of aging. Critically short telomeres trigger senescence or apoptosis.
Methods
qPCR (T/S ratio) — population mean telomere length; accessible, lower cost; SpectraCell (SpectraCell Micronutrient Test add-on), TeloYears (consumer DTC) · Flow-FISH — gold standard, measures actual length distribution across lymphocyte subsets; Life Length (Madrid/commercial labs)
Limitation
High intra-individual variability; single measurement has wide confidence intervals. Most informative as longitudinal trend over 12–24 months. Birth-length telomeres are the dominant predictor of adult telomere status — acquired loss is real but modest vs. genetic baseline.
Compound Signal
Short telomeres for age-decade (below 25th percentile on normative data) → Epithalon priority (TERT/telomerase induction via pineal peptide mechanism, Khavinson data)
Inflammatory · Laborarory Panel
Inflammaging Burden Markers
What It Measures
Chronic low-grade inflammation ("inflammaging") is a hallmark of biological aging. A composite lab panel quantifies the inflammatory burden driving accelerated aging phenotypes.
Key Markers
hsCRP (optimal: < 1.0 mg/L; > 3.0 mg/L = high cardiovascular/aging risk) · IL-6 (master inflammaging cytokine; rises with age — targets < 3.1 pg/mL) · TNF-α (NF-κB-driven; GHK-Cu modulates this pathway) · Ferritin (iron storage/inflammatory acute-phase in males; elevated ferritin correlates with accelerated aging in men) · GDF-15 (growth differentiation factor-15; emerging mortality predictor, mitokine)
Limitation
Inflammatory markers are non-specific. Acute illness, injury, or chronic disease must be excluded before interpreting as aging-driven. Lifestyle (sleep, obesity, smoking) is the dominant modifiable driver — compounds address residual burden.
Compound Signal
Elevated IL-6 + hsCRP without acute cause → BPC-157 (anti-inflammatory, VEGFR2/NO cytoprotective pathway) or Tα1 (immune-regulatory) as priority · Stable baseline inflammaging → GH axis optimization (Sermorelin/Ipamorelin) is safer first-line
Test Result → Compound Selection Guide
Short telomeres for age
→ Epithalon (TERT/telomerase, annual SC cycles); consider biological age clock testing to assess epigenetic co-pathology
Horvath age > chrono by ≥ 3 yr
→ GHK-Cu primary (Yamanaka factor activation / epigenetic reversal); consider Epithalon if telomere data also abnormal
Elevated DunedinPACE
→ Multi-axis protocol priority; GH axis (Sermorelin + Ipamorelin at bedtime) to address pace drivers including somatopause; lifestyle co-interventions required
High inflammaging burden
→ BPC-157 (VEGFR2/NO cytoprotective, gut-origin inflammaging) or Tα1 (immune-regulatory); defer GH-axis protocols until inflammaging is partially controlled
Low IGF-1 + low GH
→ Sermorelin monotherapy or Sermorelin + Ipamorelin combination; confirm normal thyroid and cortisol status before initiating (both blunt GH response if abnormal)
Multiple abnormalities
→ Prioritize by phenotype severity; avoid starting more than two new compounds simultaneously; establish baseline labs and re-test after first compound cycle before adding
Epigenetic Clocks
12 months minimum
Methylation marks turn over slowly; shorter intervals produce noise. DunedinPACE (pace-of-aging) shows change faster than static Horvath age.
Telomere Length
12–24 months
Annual telomere loss is ~40–100 bp — within most assay noise floors. Trend over multiple annual measurements is more reliable than any single test.
Inflammatory Markers
3–6 months
hsCRP, IL-6, ferritin respond to interventions (compound, lifestyle, diet) within weeks to months — most useful for monitoring response to protocol changes.
IGF-1 / GH Axis
6 weeks, then quarterly
IGF-1 responds to secretagogue therapy within 4–6 weeks. Quarterly monitoring ensures target range maintenance and detects upward drift requiring dose reduction.
Safety & Regulatory Reference
Safety & Regulatory Matrix
Longevity hub compounds span a wide range of regulatory status — from historically FDA-approved (Sermorelin as Geref, discontinued for market rather than safety reasons) to endogenous peptides with established cosmetic safety records (GHK-Cu) to investigational compounds with primarily Russian clinical data (Epithalon). WADA status applies to competitive athletes.
Compound
FDA Status
WADA 2026
Primary Route
Key Safety Notes
US Availability
Epithalon Ala-Glu-Asp-Gly · Pineal Tetrapeptide
No US Status Russian clinical research; no FDA IND or NDA; no US regulatory pathway
Not Listed
SC injection; IV (original studies)
Well-tolerated in Khavinson's human studies with no serious adverse events reported. Theoretical concern regarding telomerase activation in cells with oncogenic mutations — TERT activation in pre-existing cancer cells could theoretically support tumor survival. Absolute contraindication consideration in known active malignancy. Epigenetic effects of TERT activation beyond telomere length are not fully characterized.
Research chemical / compounding peptide. No pharmaceutical-grade standard; quality highly variable. No US licensed pharmacy produces Epithalon under GMP for approved indications.
GHK-Cu Glycyl-Histidyl-Lysine-Cu²⁺ · Endogenous
Cosmetic Ingredient GRAS cosmetic status (topical); no drug approval; 503A compounding for SC
Not Listed
Topical (established); SC (research)
Excellent topical safety profile across decades of cosmetic use. Systemic copper load is the primary concern with SC administration at higher doses — monitor serum copper and ceruloplasmin. Avoid copper supplementation simultaneously. Not recommended in Wilson's disease (copper metabolism disorder). Endogenous peptide; no mutagenicity or carcinogenicity concerns reported in published literature.
Widely available as topical cosmetic ingredient (verified commercial preparations). Compounding pharmacies offer SC formulations for research use under 503A. Relatively well-characterized supply chain vs. other longevity peptides.
Sermorelin GHRH(1-29) · Former FDA approval as Geref
Former FDA Approval Geref (Sermorelin acetate) approved for pediatric GH deficiency testing; voluntarily discontinued 2008; compounding available
Review Required
SC injection; IV (diagnostic use)
Well-characterized safety profile from Geref approval package: injection site reactions (erythema, pain, swelling), flushing, headache, hypothalamic-pituitary axis effects. GH-mediated: fluid retention, insulin resistance at higher doses. Monitor glucose and HbA1c. Contraindicated in active malignancy (GH/IGF-1 has mitogenic properties). Pituitary reserve assessment (normal pituitary function required) before initiation.
Compounding pharmacies (503A) for physician-prescribed individual patient use. Geref not commercially available since 2008 withdrawal. Some international pharmaceutical sources. FDA has not placed Sermorelin on the prohibited compounding list (unlike CJC-1295 no-DAC); compounding is currently permissible.
Ipamorelin GH Secretagogue Pentapeptide
No US Status No IND or NDA; not in FDA's approved drug database; compounding access only
Review Required
SC injection
Phase I safety data published by Novo Nordisk (original developer); no serious adverse events at therapeutic doses. Published selectivity advantage: cortisol and prolactin elevation <10% vs. older GHS peptides. Water retention from GH effect (dose-dependent). Same GH-mediated concerns as Sermorelin: insulin resistance monitoring, contraindication in malignancy. Carpal tunnel syndrome possible at high GH levels from any GH-pathway compound.
Compounding pharmacies (503A). No commercial pharmaceutical product in the US. Recent 503A compounding regulatory environment has tightened for GH-axis compounds generally; verify current 503A eligibility before prescribing. Quality highly variable across compounders.
WADA and GH Axis Compounds: Sermorelin and Ipamorelin stimulate endogenous GH production. The WADA Prohibited List prohibits "releasing factors" of GH under S2 — specifically including GHRH, growth hormone secretagogues, and growth hormone-releasing peptides. Sermorelin (a GHRH analogue) and Ipamorelin (a GHS) are likely covered under this prohibition. Athletes must obtain Therapeutic Use Exemption (TUE) with documented GH deficiency before using either compound. The indirect-GH-stimulation argument does not remove these from S2 — WADA's language explicitly covers releasing factors, not only direct GH. When in doubt, request a formal WADA review.
IGF-1 and Cancer Risk — Context for Longevity Medicine: Multiple epidemiological studies associate elevated IGF-1 with increased risk of prostate, breast, and colorectal cancer. This creates a therapeutic tension in longevity GH-axis protocols: GH restoration improves body composition and quality of life metrics, but supraphysiologic IGF-1 carries mitogenic risk. Target IGF-1 in the low-normal physiological range for age — not the upper quartile — and conduct regular cancer surveillance (PSA, mammography, colonoscopy as appropriate) in patients on GH-axis protocols.
Frequently Asked Questions
Longevity Hub — Common Questions
What is the difference between taking growth hormone directly versus using Sermorelin or Ipamorelin?
This is the most clinically important question in longevity GH-axis medicine, and the distinction matters significantly for both safety and physiological efficacy.
Exogenous GH injection: Delivers recombinant human GH directly, bypassing the hypothalamic-pituitary regulatory axis entirely. GH levels rise acutely and remain elevated based on the injected dose — the body's own feedback mechanisms are overridden. Physiological GH secretion is pulsatile (large nocturnal pulses with low daytime levels between pulses); exogenous injection produces sustained, non-pulsatile elevation. This non-physiological pattern carries insulin resistance risk disproportionate to the dose and is associated with acromegaly symptoms (joint pain, carpal tunnel, soft tissue swelling) even at sub-acromegalic doses when given continuously. Requires physician prescription and is a WADA prohibited substance (GH is on the S2 list).
Sermorelin and Ipamorelin: Stimulate the pituitary's own somatotroph cells to produce GH through the natural receptor mechanisms (GHRHR for Sermorelin; GHSR-1a for Ipamorelin). The pituitary's own regulatory machinery — including somatostatin, IGF-1 feedback, and circadian rhythm — remains intact and limits GH secretion within a physiological range. The resulting GH pulse pattern is closer to the youthful pulsatile pattern than continuous injection. Insulin resistance risk is substantially lower; acromegaly risk at appropriate doses is negligible. The physiological ceiling imposed by somatostatin feedback is a built-in safety mechanism absent with direct GH injection.
Can Epithalon actually reverse aging, or is that marketing language?
The distinction between scientifically accurate claims and marketing language for Epithalon is important to make precisely.
What the evidence actually shows: Epithalon has been demonstrated to (1) induce TERT (telomerase reverse transcriptase) gene expression in human embryonic fibroblasts, with corresponding increase in telomerase activity and measurable telomere length extension in treated cells (Khavinson 2003); (2) reduce oncogenesis markers and mammary tumor incidence in transgenic mouse models (Anisimov 2002); (3) improve NK cell cytotoxicity, T-cell ratios, and circadian melatonin secretion in elderly human subjects in the Khavinson group's clinical studies.
What the evidence does not show: No randomized controlled trial has demonstrated that Epithalon extends human lifespan, reverses aging as measured by validated clinical endpoints, or produces any benefit in young or middle-aged individuals. The human studies are primarily in elderly subjects, conducted by the Khavinson group specifically, with limited independent replication. "Reversing aging" as a statement goes beyond what these studies claim.
Accurate characterization: Epithalon is the most mechanistically well-supported peptide for telomerase activation currently in the research literature. Its human data suggests immune-aging and circadian benefits in elderly subjects. Whether telomere extension in fibroblast cultures translates to clinically meaningful lifespan or healthspan extension in humans is unknown. That is the honest, physician-level answer to this question — and it is meaningfully different from either "Epithalon reverses aging" or "there is no evidence for Epithalon."
How do telomere testing results inform Epithalon or GHK-Cu use?
Telomere length testing adds specificity to what would otherwise be empiric compound selection — it converts "I think this patient might benefit from telomere support" into "this patient's telomere length is in the bottom quartile for their age cohort." The available testing approaches differ significantly in what they measure and how actionable the results are.
Peripheral blood leukocyte telomere length (qPCR or Flow-FISH): The most widely available test (SpectraCell, LabCorp). Measures average telomere length in white blood cells. The result is compared to age-matched population norms — a result below the 25th percentile for age is often used as a threshold for "shortened telomeres." Limitation: white blood cell telomeres reflect hematopoietic stem cell telomere dynamics specifically, not telomere status in other tissues (skin, gut, muscle). The correlation between leukocyte telomere length and all-cause aging rate is statistically significant in populations but imperfect in individuals.
Telomere length plus epigenetic age (Horvath methylation clock): Some integrative testing panels combine telomere length with methylation-based biological age estimation. The methylation age gap (chronological age minus biological methylation age) is a different dimension of aging from telomere length — both can be normal, both can be abnormal, or they can diverge. GHK-Cu's Yamanaka factor activation is more relevant to the methylation age dimension; Epithalon's TERT activation is more relevant to the telomere dimension.
Clinical interpretation guidance: Telomere testing is most useful as a baseline and follow-up measure — establishing where the patient sits in relation to their age cohort before intervention, and whether intervention has produced a measurable effect on retesting. "Telomere testing says I should take peptides" is marketing; "telomere testing establishes a baseline for evaluating response to a physician-supervised protocol" is scientific.
Is there a cancer risk from activating telomerase with Epithalon?
This is a legitimate and important safety question that deserves a nuanced, accurate answer — not dismissal.
The theoretical concern: Telomerase activation is a hallmark of cancer. Approximately 90% of human cancers upregulate telomerase to achieve replicative immortality — the ability to divide indefinitely without telomere shortening triggering senescence. If Epithalon activates TERT in normal cells, could it also activate TERT in cells with early oncogenic mutations, potentially enabling those cells to escape replicative senescence and progress toward malignancy?
The pharmacological counter-argument: Epithalon's published mechanism is transcriptional activation of TERT via chromatin decondensation at the TERT promoter — a mechanism that requires the TERT promoter to be accessible. In cancer cells, TERT is already constitutively active (often through promoter mutation, gene amplification, or chromosomal rearrangement) through mechanisms that are independent of Epithalon's route. Adding Epithalon to a cell that already has TERT at maximum constitutive activity would have no additional effect. Additionally, published Khavinson animal studies show reduced cancer incidence in Epithalon-treated animals vs. controls — suggesting that telomere stabilization in normal somatic cells may protect against the genomic instability that drives oncogenesis, rather than enabling it.
Practical guidance: Known active malignancy is a reasonable contraindication to Epithalon until more direct human evidence clarifies the interaction. In cancer-free individuals, the published evidence does not suggest that physiological telomerase activation in somatic cells from Epithalon creates cancer risk — but this has not been studied in RCTs with cancer incidence as a primary endpoint. Annual cancer surveillance (age-appropriate screening) is advisable for any longevity protocol patient.
How is GHK-Cu's claimed epigenetic age reversal different from just "anti-aging skincare"?
The distinction matters because most "anti-aging skincare" addresses symptoms (wrinkles, texture, pigmentation) through surface-level mechanisms (retinoids accelerating cell turnover, hyaluronic acid hydrating the stratum corneum), while GHK-Cu's proposed epigenetic mechanism, if validated systemically, would operate at the gene regulation level — a meaningfully different category of effect.
The skincare evidence (well-established): GHK-Cu in topical preparations demonstrably stimulates collagen I, collagen III, elastin, and decorin synthesis in dermal fibroblasts; accelerates wound healing; reduces matrix metalloproteinase (MMP) activity that degrades the extracellular matrix; reduces UV-induced damage markers. These are structural effects on the dermis, well-documented and constituting the cosmeceutical case for GHK-Cu.
The epigenetic evidence (promising but preliminary): Pickart et al.'s 2015 bioinformatics analysis demonstrated GHK modulating 31.2% of genes that change significantly with aging, counteracting the aging gene expression signature. The activation of Yamanaka reprogramming transcription factors (Oct4, Sox2, Klf4) was documented in cell culture models. These transcription factors, when all four (including c-Myc) are expressed together at high levels, reprogram somatic cells to induced pluripotent stem cells (iPSCs). GHK-Cu does not reprogram cells to pluripotency — it activates a subset of these factors at levels that appear to shift the transcriptional state without full reprogramming. This is the "partial epigenetic reprogramming" concept now central to longevity biology research (and being investigated by companies like Altos Labs, BioAge, NewLimit).
Honest characterization: The bioinformatics and gene expression data are compelling as hypothesis-generating evidence. Direct demonstration that systemic GHK-Cu reduces biological age as measured by methylation clocks in humans — the test that would validate the epigenetic claim — has not been published in peer-reviewed literature. The structural/cosmetic effects are proven; the systemic epigenetic aging effects are mechanistically plausible but unconfirmed in human trials.
Can longevity peptides be combined with existing pharmacological longevity interventions like metformin or rapamycin?
Combining peptide-based longevity compounds with small-molecule longevity pharmacology (metformin, rapamycin, acarbose, NAD+ precursors like NMN/NR) is a topic of active interest in longevity medicine but is almost entirely unstudied from an interaction perspective.
Metformin: AMPK activator; inhibits mTORC1 through AMPK pathway. Theoretically complementary to Epithalon (different mechanism, telomere axis) and GHK-Cu (different mechanism, epigenetic axis). The potential interaction concern is that metformin at higher doses reduces IGF-1 levels — which could partially counteract Sermorelin/Ipamorelin GH axis protocols. Monitor IGF-1 carefully in patients on both. The TAME trial (Targeting Aging with Metformin) will provide human longevity data but not combination data.
Rapamycin: mTOR inhibitor; the most established longevity pharmacology in animal models. Rapamycin's immune suppressive effects are the primary concern when combining with Thymosin α1 or Epithalon's NK restoration mechanism — rapamycin at immunosuppressive doses and immune-activating peptides are pharmacodynamically opposed. Low-dose pulsed rapamycin ("longevity" dosing, not transplant dosing) has less immunosuppressive effect, but the interaction with these peptides is unstudied. Use extreme caution and specialist involvement.
NAD+ precursors (NMN, NR): No known mechanistic conflict with any longevity hub compound. Both NMN/NR and Epithalon/GHK-Cu target different aspects of cellular aging. The combination is additive in hypothesis but lacks any published combination trial.
General principle: The most important consideration when adding longevity peptides to a pharmacological longevity stack is the interaction check for GH-axis compounds (Sermorelin, Ipamorelin) with anything that affects insulin/IGF-1 signaling, and immune-activating peptides (Epithalon's NK restoration, Thymosin α1) with anything that suppresses immune function. Outside those two interaction zones, additive mechanisms without shared pathways are generally considered lower-risk from an interaction standpoint — but "lower risk of interaction" is not the same as "proven safe in combination."
Category Overview
Longevity Hub — Frequently Asked Questions
Questions about how this hub is organized and what the evidence does — and does not — support across the longevity peptide category as a whole, before drilling into any individual compound.
What compounds does PeptideReport.ai's Longevity Hub cover?
The Longevity Hub currently has active research profiles for Epithalon and GHK-Cu (telomere and epigenetic aging), NAD+ (a cellular redox coenzyme, not a peptide), and SS-31/Elamipretide (a mitochondria-targeted peptide). Sermorelin, Ipamorelin, and MOTS-c are listed with profiles in development. BPC-157 and Thymosin α1 are cross-listed here from the Skin & Repair Hub and Immune Hub for their longevity-relevant mechanisms, but their primary profiles live on those hubs.
Does any longevity peptide on this hub have solid human evidence for actually extending lifespan?
No. None of the compounds in this hub have randomized controlled trial evidence showing extended human lifespan. Epithalon's telomerase and immune-aging data come mainly from one research group's elderly cohort studies and animal models, GHK-Cu's epigenetic reversal evidence is largely gene-expression and cell-culture data, and NAD+ supplementation has a thin controlled-trial base relative to how heavily it is marketed. This hub presents mechanistic and preclinical research, not proof of lifespan extension.
Are any of the compounds covered here FDA-approved?
One is, narrowly. SS-31 (Elamipretide) is FDA-approved as Forzinity for muscle strength in Barth syndrome, a rare mitochondrial cardiolipin disorder — not for longevity, anti-aging, or general wellness use. Sermorelin previously held FDA approval as Geref for pediatric growth hormone deficiency testing, discontinued in 2008 for commercial reasons. Epithalon, GHK-Cu in systemic form, Ipamorelin, and NAD+ IV or oral formulations have no FDA approval for any indication.
What's the biggest gap between marketing and evidence in the longevity peptide category?
The gap is widest exactly where marketing is loudest. NAD+ IV infusion is sold heavily as an anti-aging and energy treatment despite lacking controlled human trial support. SS-31 shows the opposite pattern: it has genuine trial data and an FDA approval, but that evidence applies to a narrow rare-disease population, not to the much larger off-label wellness market using the same peptide for general mitochondrial support. Evidence for one narrow indication, or for a related compound, does not automatically transfer to broader longevity claims.
What are the main safety considerations across this category?
Safety concerns differ by mechanism: theoretical malignancy risk with telomerase activation for Epithalon, systemic copper loading for GHK-Cu, and IGF-1 and insulin-resistance monitoring for GH-axis compounds like Sermorelin and Ipamorelin. Most compounds in this hub are not FDA-approved for any longevity indication, so manufacturing quality and dosing consistency vary by source. None of these compounds should be used outside physician supervision with appropriate laboratory monitoring.
Why are BPC-157 and Thymosin α1 listed on the Longevity Hub if they have their own hubs?
BPC-157 and Thymosin α1 are cross-listed here because they act on longevity-relevant biology — BPC-157 on inflammaging and gut-barrier health, and Thymosin α1 on thymic involution and immune aging — even though their primary, most detailed profiles live on the Skin & Repair Hub and Immune Hub respectively. Cross-listing reflects that aging is multi-axis; it does not mean these compounds were developed or are specifically indicated for longevity.
Full Research Disclaimer
No compound profiled in this Longevity Research Hub is FDA-approved for longevity, anti-aging, epigenetic reversal, telomere extension, growth hormone restoration, or any other indication discussed on this page. Sermorelin (Geref) formerly held FDA approval for pediatric growth hormone deficiency testing, a use that has been discontinued; compounded Sermorelin is not an FDA-approved drug. GHK-Cu holds cosmetic ingredient status for topical formulations only — not approval for systemic aging indications. Epithalon has no US regulatory status. Ipamorelin has no FDA approval or IND status. All content is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment guidance. None of these compounds should be considered outside a physician-supervised research context. Patients with cancer, growth hormone deficiency, cardiovascular disease, autoimmune disease, or other serious medical conditions must receive treatment from qualified medical specialists and should not substitute investigational peptides for established standard-of-care therapy. WADA classifications, FDA regulatory status, and evidence base evolve continuously — this profile reflects literature and regulatory information available at time of authorship. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparation.
SD
Dr. Scott DelBoccio, DMD
Author · PeptideReport.ai
Dr. Scott DelBoccio, DMD is the author and editor of PeptideReport.ai. All hub pages and compound profiles are authored with primary literature review, E-E-A-T content standards, and physician-level mechanistic accuracy. Content reflects the current peer-reviewed evidence base and is updated as new research is published.